Treatment with Bempedoic acid in patients with statin intolerance: Preliminary report of a single centre real world study
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In that study, all patients were on ezetimibe and 16% were on PCSK9i.
“All patients were on ezetimibe and 16% were on PCSK9i [24].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [24]
In a small primary prevention study (n=19) of statin intolerant patients with hypercholesterolemia and no prior cardiovascular events, bempedoic acid added to ongoing maximally tolerated LLT reduced LDL-C by 38.5% at 1 month.
“In a small, primary prevention study (n = 19) of statin intolerant patients with hypercholesterolemia and no prior cardiovascular events, bempedoic acid added to ongoing, maximally tolerated LLT reduced LDL-C by 38.5% at 1-month follow-up (baseline LDL-C = 123 mg/dL) [24].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [24]
Real-world LDL-C reductions with bempedoic acid in primary prevention populations ranged from 23% to 39%.
“These reductions were reported across both primary (23% to 39%) [24,29,44] and secondary prevention populations (15% to 39%) [25,32,38,39].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [24]
In the same small primary prevention study, 90.0% of patients reached an LDL-C target <100 mg/dL at 1 month after initiating bempedoic acid.
“In a small, primary prevention study (n = 19), 32.0% of patients with hypercholesterolemia and statin intolerance already on maximally tolerated LLT (all patients were on ezetimibe and 16.0% on PCSK9i), achieved an LDL-C target <70 mg/dL (baseline value = 123 mg/dL), and 90.0% reached <100 mg/dL at 1 month after initiating bempedoic acid [24].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [24]
In a small primary prevention study (n = 19), 32.0% of patients with hypercholesterolemia and statin intolerance already on maximally tolerated LLT achieved an LDL-C target <70 mg/dL at 1 month after initiating bempedoic acid (baseline LDL-C = 123 mg/dL).
“In a small, primary prevention study (n = 19), 32.0% of patients with hypercholesterolemia and statin intolerance already on maximally tolerated LLT (all patients were on ezetimibe and 16.0% on PCSK9i), achieved an LDL-C target <70 mg/dL (baseline value = 123 mg/dL), and 90.0% reached <100 mg/dL at 1 month after initiating bempedoic acid [24].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [24]
LDL-C reductions with bempedoic acid in statin-intolerant patients ranged from 22% to 38%.
“Consistent effects were also seen when bempedoic acid was added to statins (15% to 39%) [25,30,32,38,39,44], and when used in statin intolerant patients (22% to 38%) [24,29,34,35,37,40,41], despite the latter group having higher baseline LDL-C.”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [24]
Cites
Still being checked.
Cited by
Sorted by citations
Systematic literature review on the real-world effectiveness and safety of bempedoic acid
Cicero, A. F. G., Cannon, C. P., Gautam, R., Anwar, S., Ghatak, A., Sarnes, E., Powell, H. A., Chhabra, R., & Jawla, S. (2026) · Atherosclerosis Plus · doi:10.1016/j.athplu.2026.100562 · Cited by 1 · see citing works
“[24,29,34,35,37,40,41], despite the latter group having higher baseline LDL-C.”
Influential
- Authors
- Donnarumma, S., Calcaterra, I., Palermo, V., De Ruberto, F., Schiano, N., Cardiero, G., Di Taranto, M. D., Iannuzzo, G., Fortunato, G., & Di Minno, M.
- Affiliations
- Federico II University Hospital (IT)
- University of Naples Federico II (IT)
- Venue
- Atherosclerosis
- Publisher
- Elsevier BV
- Published
- 2024-08
- Volume
- 395
- Pages
- 118137
- ISSN
- 0021-9150 (ISSN-L)
- OpenAlex
- W4401600305
- Cited by
- 1
- References
- 0
- Citations by year
- 2026: 1
- FWCI
- 0.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Atherosclerosis (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- bempedoic acid, statin intolerance, hypercholesterolemia, LDL cholesterol lowering, real-world evidence, lipid-lowering therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
